08049.HK
Jilin Province Huinan Changlong Bio-pharmacy Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 2.30
−1.50%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1B | 901.9M | 881.2M | 841.5M | 841.6M |
| Cost of Revenue | 170.8M | 144.2M | 195.9M | 257.5M | 193.6M |
| Gross Profit | 938.8M | 757.7M | 685.2M | 584.0M | 648.0M |
| Operating Expenses | |||||
| R&D Expense | 30.6M | — | — | 13.1M | 19.1M |
| SG&A Expense | 670.9M | 561.4M | 522.2M | 449.0M | 509.9M |
| General & Admin Expense | 98.0M | 121.3M | 173.8M | 107.0M | 105.1M |
| Selling & Marketing Expense | 335.9M | 440.0M | 348.4M | 341.9M | 404.9M |
| Other Expenses | (52.6M) | (18.3M) | (46.1M) | (76.8M) | (78.8M) |
| Total Operating Expenses | 648.9M | 543.1M | 476.1M | 385.2M | 450.2M |
| Cost and Expenses | 819.7M | 687.3M | 672.0M | 642.7M | 643.8M |
| Operating Income (EBIT) | 341.1M | 214.6M | 209.2M | 198.8M | 197.8M |
| Non-Operating | |||||
| Interest Income | — | 48.7M | 18.8M | 33.1M | 35.3M |
| Interest Expense | 2.1M | 1.4M | 2.0M | 515.0K | 477.0K |
| Net Interest Income | 21.2M | 47.3M | 16.7M | 32.6M | 34.8M |
| Other Non-Op Income/Expense | 74.7M | 49.9M | (2.0M) | (515.0K) | (477.0K) |
| Non-Operating Income (excl Interest) | 50.4M | (51.2M) | — | — | — |
| EBT (Pre-Tax Income) | 364.6M | 264.5M | 207.2M | 198.3M | 197.3M |
| Income Tax Expense | 86.2M | 65.6M | 22.9M | 50.1M | 3.8M |
| Bottom Line | |||||
| Net Income | 278.4M | 198.9M | 184.3M | 148.2M | 193.6M |
| Earnings from Cont. Ops | 278.4M | 198.9M | 184.3M | 148.2M | 193.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 278.4M | 198.9M | 184.3M | 148.2M | 193.6M |
| Per Share | |||||
| Basic EPS | HK$0.50 | HK$0.35 | HK$0.33 | HK$0.26 | HK$0.35 |
| Diluted EPS | HK$0.50 | HK$0.35 | HK$0.33 | HK$0.26 | HK$0.35 |
| Revenue Per Share | HK$1.98 | HK$1.61 | HK$1.57 | HK$1.50 | HK$1.50 |
| Shares | |||||
| Basic Shares Outstanding | 560.3M | 560.3M | 560.3M | 560.3M | 560.3M |
| Diluted Shares Outstanding | 560.3M | 560.3M | 560.3M | 560.3M | 560.3M |
| Profitability Metrics | |||||
| EBITDA | 376.9M | 294.2M | 236.3M | 226.4M | 231.4M |
| D&A | 35.7M | 28.3M | 27.1M | 27.6M | 33.6M |
| EBIT | 290.7M | 265.9M | 209.2M | 198.8M | 197.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026